Table 2.
Accessible published dosimetric parameters associated with ORNJ incidence.
| Reference | Study Year | Patients (N) |
Tumor Primary | Recommended Parameter |
|---|---|---|---|---|
| Kubota et al. [74] | 2021 | 616 | HNC | V60 ≤ 14% |
| MD Anderson Head and Neck Cancer Symptom Working Group [75] | 2017 | 68 | OPC | V44 < 42% V58 < 25% |
| De Felice et al. [76] | 2016 | 36 | HNC | Dmean < 57.6 Gy D2% < 65 |
| van Dijk et al. [77] | 2021 | 1259 | HNC | For <5% ORNJ: D30% < 42 Gy (without tooth extraction) For <5% ORNJ: D30% < 35 Gy (without tooth extraction) |
| Aarup-Kristensen et al. [8] | 2021 | 1224 | HNC | Dmean < 37 Gy |
| Tsai et al. [78] | 2013 | 402 | OPC | Dmean < 37.5 Gy V50 (continously) V60 (continously) |
| Caparrotti et al. [11] | 2017 | 1196 | OPC | V50 (continously) V60 (continously) |
| Lang et al. [79] | 2022 | 89 | OCC | Dmean ≤ 45 Gy Dmax ≤ 60 Gy PTV proportion intersecting the mandible ≤ 40% |
| DeLuke et al. [80] | 2022 | 83 | HNC | V50 (continously) V65 (continously) |
| Lee et al. [81] | 2022 | 174 | OPC | V44 (continously) V58 (continously) |
| Yilmaz et al. [68] | 2023 | 263 | NPC | V59.8 ≥ 36% Gy |
Abbreviations: HNC: Head and neck cancer; OPC: Oropharyngeal cancer; OCC: Oral cavity cancer; NPC; Nasopharyngeal cancer; ORNJ: Osteoradionecrosis of the jaw; Vx: Volume receiving X Gray or higher dose: Dx: Percentage of the prescription dose received by the X% of the mandible; Dmean: Mean dose: Dmax: Maximum dose; PTV: Planning target volume.